You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

NATRECOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Natrecor patents expire, and what generic alternatives are available?

Natrecor is a drug marketed by Scios Llc and is included in one NDA.

The generic ingredient in NATRECOR is nesiritide recombinant. There are two drug master file entries for this compound. Additional details are available on the nesiritide recombinant profile page.

Summary for NATRECOR
Drug patent expirations by year for NATRECOR
Drug Prices for NATRECOR

See drug prices for NATRECOR

Recent Clinical Trials for NATRECOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Virginia Commonwealth UniversityPhase 4
John C BurnettPhase 1/Phase 2
Mayo ClinicPhase 1/Phase 2

See all NATRECOR clinical trials

US Patents and Regulatory Information for NATRECOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Scios Llc NATRECOR nesiritide recombinant FOR SOLUTION;INTRAVENOUS 020920-001 Aug 10, 2001 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NATRECOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Scios Llc NATRECOR nesiritide recombinant FOR SOLUTION;INTRAVENOUS 020920-001 Aug 10, 2001 ⤷  Try a Trial ⤷  Try a Trial
Scios Llc NATRECOR nesiritide recombinant FOR SOLUTION;INTRAVENOUS 020920-001 Aug 10, 2001 ⤷  Try a Trial ⤷  Try a Trial
Scios Llc NATRECOR nesiritide recombinant FOR SOLUTION;INTRAVENOUS 020920-001 Aug 10, 2001 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for NATRECOR

See the table below for patents covering NATRECOR around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 0418308 TECHNIQUES RECOMBINANTES DE PRODUCTION DE NOUVEAUX PEPTIDES NATRIURETIQUES ET VASODILATATEURS. (RECOMBINANT TECHNIQUES FOR PRODUCTION OF NOVEL NATRIURETIC AND VASODILATOR PEPTIDES.) ⤷  Try a Trial
Canada 1339210 TECHNIQUES RECOMBINANTES POUR LA PRODUCTION DE NOUVEAUX NATRIURETIQUES ET DE PEPTIDES VASODILATATEURS (RECOMBINANT TECHNIQUES FOR PRODUCTION OF NOVEL NATRIURETIC AND VASODILATOR PEPTIDES) ⤷  Try a Trial
Australia 3768189 ⤷  Try a Trial
Germany 68923878 ⤷  Try a Trial
Austria 126522 ⤷  Try a Trial
Ireland 68889 Recombinant techniques for production of novel natriuretic and vasodilator peptides ⤷  Try a Trial
Ireland 891792 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.